FMP

FMP

Enter

ZTS - Zoetis Inc.

photo-url-https://images.financialmodelingprep.com/symbol/ZTS.png

Zoetis Inc.

ZTS

NYSE

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

153.54 USD

0.07 (0.04559%)

About

ceo

Ms. Kristin C. Peck

sector

Healthcare

industry

Drug Manufacturers - Specialty & Generic

exchange

NYSE

Description

Zoetis Inc. discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses. The company also offers vaccines, which are biological preparations to prevent diseases of the respiratory, gastrointestinal, and reproductive tracts or induce a specific immune response; anti-infectives that prevent, kill, or slow the growth of bacteria, fungi, or protozoa; and parasiticides that prevent or eliminate external and internal parasites, which include fleas, ticks, and worms. It also provides other pharmaceutical products that comprise pain and sedation, antiemetic, reproductive, and oncology products; dermatology products for itch associated with allergic conditions and atopic dermatitis; and medicated feed additives, which offer medicines to livestock. In addition, the company provides portable blood and urine analysis testing, including point-of-care diagnostic products, instruments and reagents, rapid immunoassay tests, reference laboratory kits and services, and blood glucose monitors; and other non-pharmaceutical products, including nutritionals and agribusiness services, as well as products and services in areas, such as biodevices, genetics tests, and precision animal health. It markets its products to veterinarians, livestock producers, and retail outlets, as well as third-party veterinary distributors through its sales representatives, and technical and veterinary operations specialists. The company was founded in 1952 and is headquartered in Parsippany, New Jersey.

CIK

0001555280

ISIN

US98978V1035

CUSIP

98978V103

Address

10 Sylvan Way

Phone

973 822 7000

Country

US

Employee

13,800

IPO Date

Feb 1, 2013

Key Executives

Name

Title

Pay

Year Born

Mr. Wetteny N. Joseph CPA

Executive Vice President & Chief Financi...

1.9M

1972

Ms. Roxanne Lagano

Executive Vice President, General Counse...

1.37M

1965

Mr. Jamie Brannan

Executive Vice President & Chief Commerc...

1.81M

1973

Ms. Julie A. Fuller

Executive Vice President, Chief Human Re...

0

1972

Mr. Steven Frank

Vice President of Investor Relations

0

N/A

Mr. Keith Sarbaugh

Executive Vice President & Chief Digital...

0

1979

Dr. Robert J. Polzer Ph.D.

Executive Vice President and President o...

1.52M

1969

Ms. Jeannette Ferran Astorga

Executive Vice President of Corporate Af...

0

1975

Mr. Nick Ashton

Executive Vice President and President o...

0

1973

Ms. Kristin C. Peck

Chief Executive Officer & Director

4.46M

1971

As of December 31, 2024, the total employee count stands at 13,800, with compensation values reflecting the last fiscal year ending on that date. Pay encompasses salary, bonuses, etc., All figures are in USD.

FMP

FMP

Financial Modeling Prep API provides real time stock price, company financial statements, major index prices, stock historical data, forex real time rate and cryptocurrencies. Financial Modeling Prep stock price API is in real time, the company reports can be found in quarter or annual format, and goes back 30 years in history.
twitterlinkedin
2017-2025 © Financial Modeling Prep